Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

ed by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

 

 

 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2013December 31,
2012(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

$

20,086,799$

5,646,021Short-term investments

7,978,3458,034,001Accounts receivable

1,029,158830,433Accounts receivable from affiliated entity

43,53736,234Prepaid expenses and other current assets

283,044471,328Prepaid expenses and other current assets from affiliate
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... , Evelyn McGown, Ph.D., Jinfang Liao, M.D., Ph.D., Molecular ... Olivier Dery, BD Biosciences Clontech, Palo Alto, CA. ... INTRODUCTION , Proteins inside eukaryotic ... balance between synthesis and degradation. Whereas protein synthesis is ...
... A. Gagne, E. Robitaille, M. Harvey, J.-A. St. Pierre, D. ... Introduction , High throughput ... process is typically highly automated and can provide screening rates over 100,000 ... simple, preferably mix and read type assays, where all reagents necessary to ...
... , This study demonstrated ... platform for a helicase functional assay. Helicase activity was measured on ... the oligos was biotinylated; the other was 5' end-labeled with [ ... a [ 33 P]-biotinylated DNA duplex substrate, then immobilized on the ...
Cached Biology Technology:Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers 2Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers 3Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers 4Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers 5Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers 2Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers 3Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers 4Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers 5Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers 6Evaluation of FlashPlate in a Helicase Assay 2Evaluation of FlashPlate in a Helicase Assay 3
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
(Date:7/25/2014)... reach puberty is influenced by ,imprinted genes,a subset of genes ... This is the first evidence that imprinted genes can ... this study were published today in the journal Nature ... is a marker for the timing of puberty in females. ... between girls, is an inherited trait, and is linked to ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2Could age of first period influence development of diseases in older women? 2
... the International Symposium " Nature and Governance Biodiversity Data, Science, ... 11 to 12 February. The symposium aimed at clarifying and popularizing ... Meeting held from 13 to 15 February 2013. The ... and brought together high-ranking speakers and guests from across the world ...
... chair!" That command given by countless parents to their ... a robot that is actually a computerized model of a ... a University of Iowa research program. That,s because a ... to accurately predict the role posture plays in transferring the ...
... A team of UCLA-led researchers has identified a protein ... as a weapon against deadly human pathogenic viruses such ... designated "priority pathogens" for national biosecurity purposes by the ... In a study published in the January issue ...
Cached Biology News:Virtual vehicle vibrations 2Newly identified natural protein blocks HIV, other deadly viruses 2
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
... Cosmid Cloning Kit enables you to prepare, ... unbiased primary cosmid library of genomic DNA ... sublibraries. High efficiency cosmid library construction is ... protocols. First, genomic DNA is randomly sheared ...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
Biology Products: